Who Should Treat Fatty Liver Disease: Primary Care or Hepatology?
Danielle Brandman – 2 July 2019
Hypotension in Cirrhosis
Ravi S. Vora, Ram M. Subramanian – 2 July 2019
Combined Heart and Liver Transplant: Indication, Patient Selection, and Allocation Policy
Kai Zhao, Rhondalyn C. Mclean, Maarouf A. Hoteit, Kim M. Olthoff – 2 July 2019
Case Study: Advanced Hepatocellular Carcinoma With Tumor Thrombus
Patrick M. Horne – 2 July 2019
Does the Liver Provide Immunosuppressive Advantage?
Josh Levitsky – 2 July 2019
Case Study: Advanced Hepatocellular Carcinoma With Tumor Thrombus
Patrick M. Horne – 2 July 2019
Myth: Liver Transplant Provides a Cure for Liver Disease
Adam VanHuis, Veronica Loy – 2 July 2019
Simultaneous Liver‐Kidney Transplant: Long‐Term Management (Steroid Withdrawal and Safety Net Patients)
Alexander C. Wiseman – 2 July 2019
Issue Information
1 July 2019
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study
Maureen M. Jonas, Robert H. Squires, Susan M. Rhee, Chih‐Wei Lin, Kazuhiko Bessho, Cornelia Feiterna‐Sperling, Loreto Hierro, Deirdre Kelly, Simon C. Ling, Tatiana Strokova, Antonio Valle‐Segarra, Sandra Lovell, Wei Liu, Teresa I. Ng, Ariel Porcalla, Yuri Sanchez Gonzalez, Margaret Burroughs, Etienne Sokal – 29 June 2019 – The pangenotypic regimen of glecaprevir and pibrentasvir (G/P) is approved to treat adults with chronic hepatitis C virus (HCV) infection and has yielded high cure rates in adults in clinical trials. Approved treatment options for pediatrics may include ribavirin.